• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用减低强度预处理方案和抗胸腺细胞球蛋白的情况下,输注的 CD34+ 细胞数量并不影响移植物抗宿主病的发生率或异基因 PBSC 移植的结局。

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin.

机构信息

BMT and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

出版信息

Bone Marrow Transplant. 2010 Jul;45(7):1189-96. doi: 10.1038/bmt.2009.331. Epub 2009 Nov 30.

DOI:10.1038/bmt.2009.331
PMID:19946341
Abstract

The influence of graft composition on the outcome of reduced-intensity (RIC) allogeneic PBSC transplantation (allo-PBSC) remains controversial. In this study, we analyzed the impact of CD34+ cell dose on the incidence of GVHD, and on the outcome after allo-PBSC, in 103 patients with hematological malignancies, using a uniform RIC regimen. The following variables were included in statistical analysis: (1) number of C34+ cells, (2) high-risk vs low-risk disease status, (3) matched related vs matched unrelated donor, (4) female donor to male recipient vs any other combination, (5) age of recipient (above vs below the median). Univariate and multivariate analysis did not reveal any association between CD34+ cell dose and acute grade-2 to grade-4, cGVHD, non-relapse mortality (NRM), relapse rate (RR) and OS. High-risk disease status was the only variable independently associated with increased NRM (P=0.001), increased RR (P=0.012) and decreased OS (P<0.001). The same results were obtained when analysis was restricted to a subgroup of 55 patients with myeloid neoplasms. The influence of graft composition on the outcome of RIC allo-PBSC should be further investigated via well-controlled randomized prospective studies.

摘要

移植物组成对低强度(RIC)异基因 PBSC 移植(allo-PBSC)结局的影响仍存在争议。在这项研究中,我们使用统一的 RIC 方案,分析了 103 例血液系统恶性肿瘤患者中 CD34+细胞剂量对 GVHD 发生率以及 allo-PBSC 后结局的影响。在统计分析中包括以下变量:(1)C34+细胞数量,(2)高危与低危疾病状态,(3)匹配相关供体与匹配无关供体,(4)女性供体给男性受者与任何其他组合,(5)受者年龄(高于或低于中位数)。单因素和多因素分析均未显示 CD34+细胞剂量与急性 2 至 4 级、cGVHD、非复发死亡率(NRM)、复发率(RR)和 OS 之间存在任何关联。高危疾病状态是唯一与增加 NRM(P=0.001)、增加 RR(P=0.012)和降低 OS(P<0.001)相关的独立变量。当将分析限制在 55 例骨髓增生性肿瘤患者的亚组中时,也得到了相同的结果。需要通过精心设计的前瞻性随机对照研究进一步探讨移植物组成对 RIC allo-PBSC 结局的影响。

相似文献

1
The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin.采用减低强度预处理方案和抗胸腺细胞球蛋白的情况下,输注的 CD34+ 细胞数量并不影响移植物抗宿主病的发生率或异基因 PBSC 移植的结局。
Bone Marrow Transplant. 2010 Jul;45(7):1189-96. doi: 10.1038/bmt.2009.331. Epub 2009 Nov 30.
2
CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.CD8 + T细胞剂量影响减低预处理异基因外周血干细胞移植后急性移植物抗宿主病的发生。
Exp Hematol. 2004 Nov;32(11):1097-102. doi: 10.1016/j.exphem.2004.07.020.
3
Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.在患有临床晚期疾病的减低强度预处理异基因移植受者中,更高剂量的CD34+祖细胞与总体生存率提高相关,且不会增加移植物抗宿主病(GVHD)。
J Clin Apher. 2013 Oct;28(5):349-55. doi: 10.1002/jca.21278. Epub 2013 May 16.
4
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.预处理方案强度对异基因移植后急性和慢性移植物抗宿主病特征的影响。
Br J Haematol. 2005 Aug;130(3):394-403. doi: 10.1111/j.1365-2141.2005.05614.x.
5
Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.供体对粒细胞集落刺激因子(G-CSF)的内在反应是异基因外周血干细胞移植后急性移植物抗宿主病的最佳预测指标。
Exp Hematol. 2006 Jan;34(1):107-14. doi: 10.1016/j.exphem.2005.09.013.
6
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.采用降低强度预处理,随后进行CD34选择的干细胞和≤10⁶/kg T细胞的同种异体移植,可能会对移植相关死亡率产生不利影响。
Ann Hematol. 2005 May;84(5):331-8. doi: 10.1007/s00277-004-1001-5. Epub 2005 Feb 23.
7
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
8
Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.在接受来自人类白细胞抗原(HLA)匹配的同胞供者的异基因外周血干细胞移植后,较高剂量自然杀伤细胞移植与更好的非复发死亡率和感染事件结局相关。
Eur J Haematol. 2005 Oct;75(4):299-308. doi: 10.1111/j.1600-0609.2005.00514.x.
9
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.在减低剂量预处理或清髓性预处理的异基因 HLA 全相合同胞供者移植治疗多发性骨髓瘤中使用的外周血或骨髓细胞。
Haematologica. 2007 Nov;92(11):1513-8. doi: 10.3324/haematol.11353.
10
Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.血液系统恶性肿瘤患者异基因干细胞移植的传统与降低强度预处理方案
Eur J Haematol. 2005 Feb;74(2):144-51. doi: 10.1111/j.1600-0609.2004.00360.x.

引用本文的文献

1
Impact of conditioning regimen on peripheral blood hematopoietic cell transplant.预处理方案对外周血造血细胞移植的影响。
World J Clin Oncol. 2019 Feb 24;10(2):86-97. doi: 10.5306/wjco.v10.i2.86.
2
Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.在减低预处理强度的动员外周血异基因造血细胞移植中,输注的总有核细胞剂量比CD34+细胞数量更能预测移植结果。
Haematologica. 2016 Apr;101(4):499-505. doi: 10.3324/haematol.2015.134841. Epub 2016 Jan 14.
3
Impact of CD34+ cell dose in children who receive unrelated PBSCT with in vivo T-cell depletion for hematologic malignancies.
接受体内T细胞去除的无关供者外周血干细胞移植治疗血液系统恶性肿瘤的儿童中CD34+细胞剂量的影响
Bone Marrow Transplant. 2015 Jan;50(1):68-73. doi: 10.1038/bmt.2014.202. Epub 2014 Sep 29.
4
The role of microglia in human disease: therapeutic tool or target?小胶质细胞在人类疾病中的作用:治疗工具还是靶点?
Acta Neuropathol. 2014 Sep;128(3):363-80. doi: 10.1007/s00401-014-1330-y. Epub 2014 Aug 9.
5
Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.采用减低剂量预处理方案的异基因干细胞移植后中重度肝静脉闭塞病的发生率及危险因素
Bone Marrow Transplant. 2014 Nov;49(11):1389-92. doi: 10.1038/bmt.2014.168. Epub 2014 Jul 28.
6
Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy.X连锁肾上腺脑白质营养不良的造血干细胞移植和造血干细胞基因治疗
Brain Pathol. 2010 Jul;20(4):857-62. doi: 10.1111/j.1750-3639.2010.00394.x.